Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - Salmonellosis : Article by

Quick Find
Authors & Editors
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
References

Related Articles
Campylobacter Infections

Cryptosporidiosis

Cyclospora

Escherichia Coli Infections

Listeria Monocytogenes

Shigellosis

Vibrio Infections

Yersinia Enterocolitica




Patient Education
Click here for patient education.



Author: Michael Zapor, MD, PhD, Clinic Chief, Infectious Diseases Service, Department of Medicine, Walter Reed Army Medical Center and Assistant Professor of Medicine, Uniformed Services University of the Health Sciences

Michael Zapor is a member of the following medical societies: American College of Physicians, American Medical Association, American Society for Microbiology, Association of Military Surgeons of the US, Infectious Diseases Society of America, and Sigma Xi

Coauthor(s): David P Dooley, MD, Chief, Associate Fellowship Director, Department of Medicine, Infectious Disease Service, Brooke Army Medical Center; Associate Professor, Department of Medicine, University of Texas at San Antonio

Editors: Mary Nettleman, MD, MS, Chair, Department of Medicine, Michigan State University; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Michael Stuart Bronze, MD, Professor, Stewart G Wolf Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Eleftherios Mylonakis, MD, Clinical and Research Fellow, Department of Internal Medicine, Division of Infectious Diseases, Massachusetts General Hospital; Burke A Cunha, MD, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Author and Editor Disclosure

Synonyms and related keywords: salmonellae, Enterobacteriaceae, enteric pathogens, food-borne illness, Salmonella choleraesuis, Salmonella typhi, Salmonella paratyphi, Salmonella typhimurium, Salmonella enteritidis, Salmonella heidelberg, S choleraesuis, S typhi, S paratyphi, S typhimurium, S enteritidis, S heidelberg, enteric fever, typhoid fever, bacteremia, endovascular infections, osteomyelitis, Salmonella enterica, S enterica, nontyphoid Salmonella infection, gastroenteritis, Salmonella enteritidis heidelberg, S enteritidis heidelberg, Salmonella enteritidis newport, S enteritidis newport, Salmonella hadar, S hadar, Salmonella enteritidis agona, S enteritidis agona, Salmonella enteritidis montevideo, S enteritidis montevideo, Salmonella oranienburg, S oranienburg, Salmonella muenchen, S muenchen, Salmonella enteritidis thompson, S enteritidis thompson, Salmonella gastroenteritis

Background

First described in 1880 and cultured in 1884, salmonellae are motile, gram-negative, rod-shaped bacteria of the family Enterobacteriaceae. Named after Daniel E. Salmon, the pathologist who first isolated the organism from porcine intestine, salmonellae are common in the gastrointestinal tracts of mammals, reptiles, birds, and insects.

As with the closely related bacterium Escherichia coli, salmonellae are potential enteric pathogens and a leading cause of bacterial food-borne illness. Additionally, salmonellae have been implicated in a spectrum of other diseases, including enteric or typhoid fever (primarily Salmonella typhi and Salmonella paratyphi), bacteremia, endovascular infections, focal infections (eg, osteomyelitis), and enterocolitis (typically Salmonella typhimurium, Salmonella enteritidis, and Salmonella heidelberg).

All salmonellae are grouped into a single overarching species. This species, Salmonella choleraesuis, is divided into 7 subgroups based on DNA homology and host range. Most of the salmonellae that are pathogenic in humans belong to a single subgroup (subgroup I). Additionally, each of the salmonellae can be serotyped according to their particular complement of somatic O, surface Vi, and flagellar H antigens. Presently, more than 2,300 Salmonella serovars exist.

Salmonellae can be isolated in the microbiology laboratory using a number of low-selective media (MacConkey agar, deoxycholate agar), intermediate-selective media (Salmonella-Shigella [SS] agar, Hektoen [HE] agar), and highly selective media (selenite agar with brilliant green). Individual isolates can then be distinguished by serotyping, bacteriophage typing, and genotyping.

Pathophysiology

The transmission of salmonellae to a susceptible host usually occurs by consumption of contaminated foods. The most common sources of salmonellae are beef, poultry, and eggs. In one recent estimate, consumption of egg shell fragments contaminated with Salmonella enterica serovar Enteritidis was responsible for approximately 182,060 cases of enteritis in the United States in the year 2000. Improperly prepared fruits, vegetables, dairy products, and shellfish have also been implicated as sources of Salmonella. Moreover, human-to-human and animal-to-human transmission can occur. For example, amphibian and reptile exposure is associated with approximately 74,000 Salmonella infections annually in the United States. Recently, cats have also been implicated as a potential reservoir.

Although the infectious dose varies among strains, a large inoculum is thought to be necessary to overcome stomach acidity and to compete with normal intestinal flora. Large inocula are also associated with higher rates of illness and shorter incubation periods. However, lower infectious doses may be adequate to cause infection if these organisms are co-ingested with foods that rapidly transit the stomach (eg, liquids) or that raise gastric pH (eg, cheese, milk), if antacids are used concomitantly, or if these organisms are ingested by individuals with impaired immune systems.

After ingestion, infection with salmonellae is characterized by attachment of the bacteria by fimbriae or pili to cells lining the intestinal lumen. Salmonellae selectively attach to specialized epithelial cells (M cells) of the Peyer patches. The bacteria are then internalized by receptor-mediated endocytosis and transported within phagosomes to the lamina propria, where they are released. Once there, salmonellae induce an influx of macrophages (typhoidal strains) or neutrophils (nontyphoidal strains). Although nontyphoid salmonellae generally precipitate a localized response, S typhi and other especially virulent strains invade deeper tissues via lymphatics and capillaries and elicit a major immune response.

Virulence factors of salmonellae are complex and encoded both on the organism's chromosome and on large (34-120 kd) plasmids. Some areas of active investigation include the means by which salmonellae attach to and invade the intestine, survive within phagosomes, effect a massive efflux of electrolytes and water into the intestinal lumen, and develop drug resistance. Several Salmonella pathogenicity islands have been identified that mediate uptake of the bacteria into epithelial cells (type III secretion system [TTSS]), nonphagocytic cell invasion (Salmonella pathogenicity-island 1 [SPI-1]), and survival and replication within macrophages (Salmonella pathogenicity-island 2 [SPI-2], phoP/phoQ).

The severity of illness in individuals infected with salmonellae is determined not only by the virulence factors of the infecting strain but by host properties as well. For example, individuals at the extremes of age (ie, people who are very young or very old) are at an increased risk for bacteremia. Similarly, systemic lupus erythematosus, malignancies, and immune deficiency are also associated with increased risk of bacteremia.

Frequency

United States

In 1997, the estimated annual incidence of salmonellosis was 13.8 cases per 100,000 people; however, most cases are unreported, and the true incidence may be much higher. Although the incidence is greatest among children, outbreaks are common among individuals who are institutionalized and residents of nursing homes. Far fewer cases of typhoid fever occur each year (0.2 per 100,000 people), and these are increasingly associated with travel to developing countries (currently 72% of cases).

International

In many countries, the incidence of salmonellosis has markedly increased; however, a paucity of good surveillance data exists. An estimated 12-33 million cases of typhoid fever occur globally each year, and the disease is endemic in many developing countries of the Indian subcontinent, South and Central America, and Africa. Outbreaks of typhoid fever have also occurred amidst the recent social upheaval of Eastern Europe.

Mortality/Morbidity

Infection with nontyphoidal salmonellae typically produces a self-limiting gastroenteritis, and dehydrated patients occasionally require hospitalization. Still, death rarely occurs. For example, the mortality rate associated with S enteritidis outbreaks in the United States from 1985-1991 was 0.4%. Case-fatality rates were 70 times higher in nursing homes and hospitals. Mortality rates from typhoid fever are similarly low in the United States (<1%), but mortality rates of 10-30% have been reported in certain Asian and African countries. Between 1996 and 1999, an estimated 1.4 million nontyphoid Salmonella infections occurred in the United States, with an estimated 15,000 hospitalizations and 400 deaths annually. A related study during the same period found that 22% of people infected with nontyphoid Salmonella required hospitalization, with an annual incidence of 0.08 deaths per 100,000 population.

  • Although uncommon, extraintestinal complications of salmonellosis caused by seeding of bacteria to other organs are associated with increased mortality rates. Such complications include endocarditis and arterial infections, cholecystitis, hepatic and splenic abscesses, urinary tract infections, pneumonia or empyema, meningitis, septic arthritis, and osteomyelitis.
  • Resistance to quinolone antibiotics has also been associated with a 3.15-fold increased risk of invasiveness or death with infection by S typhimurium.

Race

The disease has no predilection for a particular race.

Sex

The disease has no predilection for either sex.

Age

The incidence of salmonellosis in the United States is greatest among children younger than 5 years (61.8 per 100,000 people), with a peak among those younger than 1 year. Infants and people older than 60 years are most susceptible and tend to have more severe infections. In one 4-year surveillance study, 47% of people hospitalized with nontyphoid Salmonella infections were older than 60 years.



History

Salmonella infections typically produce 1 of 3 distinct syndromes: gastroenteritis, typhoid (enteric) fever, or focal disease.

  • Infection with nontyphoidal salmonellae usually causes enterocolitis similar to that caused by other bacterial enteric pathogens.
  • Nausea, vomiting, and diarrhea occur within 6-48 hours after ingestion of contaminated food or drink.
  • In most cases, stools are loose and bloodless. Salmonellae may rarely cause large-volume choleralike diarrhea or may be associated with tenesmus.
    • The diarrhea is typically self-limiting and resolves within 3-7 days.
    • While an initial transient diarrhea may occur, established infections with S typhi or S paratyphi are associated with abdominal pain and either constipation (~40%) or recurrent diarrhea (~40%).
  • Fever, abdominal cramping, chills, headache, and myalgia are common.
    • Fever usually resolves within 48 hours.
    • Enteric fever (typically caused by S typhi or S paratyphi) is generally an acute illness manifested by fever, headache, and abdominal symptoms and should be considered in travelers returning from tropical and subtropical areas.
  • Focal disease is variable and defined by the site of infection.

Physical

Patients with Salmonella gastroenteritis typically have a self-limiting fever (38-39°C) within 48 hours of ingestion. A prolonged persistent fever (4-8 wk in untreated individuals) that increases daily (as high as 41°C) suggests typhoid fever. Nontyphoidal gastroenteritis is generally limited to diarrhea, although typhoid (enteric) fever may present with both gastrointestinal and skin manifestations (ie, rose spots). The following organ systems may be involved with Salmonella infection:

  • Gastrointestinal: Salmonella infections typically cause nonbloody loose stool or watery diarrhea. Abdominal tenderness (~50%) and mild hepatosplenomegaly (~50%) are both common in patients with typhoid fever.
  • Cardiovascular: Salmonella infections (commonly S typhimurium or S choleraesuis) may produce arterial infections or endocarditis.
  • Pulmonary: Salmonella pneumonia or empyema is rare in the absence of comorbid illnesses such as underlying lung disease, malignancy, diabetes, sickle cell anemia, or alcohol abuse.
  • Genitourinary: Individuals with urolithiasis or structural abnormalities or individuals who are undergoing immunosuppressive therapy are predisposed to Salmonella urinary tract infections.
  • Neurologic: Salmonella meningitis may rarely occur, typically in infants and young children.
  • Skeletal: Infection with salmonellae may cause septic arthritis and osteomyelitis. The latter affects the long bones and typically occurs in patients with sickle cell disease.
  • Integument: Enteric fever may be associated with pink, blanchable, slightly raised macules (rose spots) on the chest and abdomen.

Causes

  • In 1994, the 10 most frequently isolated Salmonella strains causing human disease were reported to the US Centers for Disease Control and Prevention as the following:
    • S enteritidis (26.1%)
    • S typhimurium (22.1%)
    • S enteritidis heidelberg (4.8%)
    • Salmonella enteritidis newport (4.3%)
    • Salmonella hadar (2.7%)
    • Salmonella enteritidis agona (2.0%)
    • Salmonella enteritidis montevideo (1.7%)
    • Salmonella oranienburg (1.6%)
    • Salmonella muenchen (1.5%)
    • Salmonella enteritidis thompson (1.5%)



Campylobacter Infections
Cryptosporidiosis
Cyclospora
Escherichia Coli Infections
Listeria Monocytogenes
Shigellosis
Vibrio Infections
Yersinia Enterocolitica

Other Problems to be Considered

Ingestion of preformed toxins (eg, staphylococci, botulin, bacilli)



Lab Studies

  • Bacteriology
    • Freshly passed stool is the preferred specimen for the isolation of nontyphoidal Salmonella species. Various selective media are routinely used, including MacConkey agar, eosin-methylene blue (EMB) agar, HE agar, SS agar, and xylose-lysine-deoxycholate (XLD) agar.
    • In cases of typhoid fever, S typhi or S paratyphi may be isolated from stool, urine, or rose spot biopsy and from gastric or intestinal secretions, although blood and bone marrow aspirates have the highest yields.
    • Salmonella species may be differentiated by conventional biochemical assays, phage typing, and serological typing.
  • Hematology: Although the white blood cell count is usually within reference ranges, approximately one fourth of patients with typhoid fever are leukopenic, neutropenic, or anemic.

Other Tests

  • Specialized laboratories may use phage typing, plasmid analysis, ribotyping, pulsed field gel electrophoresis, and polymerase chain reaction when diagnosing salmonellosis.



Medical Care

Salmonella gastroenteritis is usually a self-limiting disease. Direct therapy at fluid and electrolyte replacement. Because antibiotics do not appear to shorten the duration of symptoms and actually prolong the duration of convalescent carriage, they are not routinely used to treat uncomplicated nontyphoidal Salmonella gastroenteritis. Current recommendations are that antibiotics should be reserved for patients with severe disease or patients who are at a high risk of invasive disease.

Historically, recommended oral regimens for the treatment of typhoid fever included ampicillin, trimethoprim-sulfamethoxazole, or chloramphenicol. However, emerging drug resistance has limited the usefulness of these antibiotics. Presently, quinolone, macrolide, and third-generation cephalosporin antibiotics are preferred for empiric therapy. However, resistance to these drugs has also been reported.

  • Although still uncommon in the United States, resistance to quinolone antibiotics among typhoidal and nontyphoidal salmonellae is increasingly common elsewhere. In one 22-year surveillance study in Spain, the prevalence of nalidixic acid resistance increased almost 80-fold to 38.5%.
  • In a recent review of US data from the National Antimicrobial Resistance Monitoring System, 58% of S typhimurium isolated between 1997 and 1998 were resistant to at least one antibiotic, and 3 multidrug-resistant strains (resistant to 5 or more antibiotics) accounted for 74% of isolates.

Surgical Care

Typhoid fever may occasionally be complicated by intestinal perforation or hemorrhage, cholecystitis, endocarditis, arteritis, osteomyelitis, or soft tissue abscess formation, necessitating surgical intervention. Moreover, long-term carriage with S typhi (usually with the gallbladder as the reservoir) may necessitate cholecystectomy.



The goals or pharmacotherapy are to eradicate infection, reduce morbidity, and prevent complications.

Drug Category: Antibiotics

Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting.

Drug NameCiprofloxacin (Cipro)
DescriptionFluoroquinolone with activity against MRSA, pseudomonad species, streptococcal species, Salmonella epidermidis, and most gram-negative organisms, but no activity against anaerobes. Inhibits bacterial DNA synthesis and, consequently, growth.
Adult DoseGastroenteritis: 500 mg PO bid for 7 d
Typhoid fever: 400 mg IV bid, then switch to PO when tolerated for a total course of 10 d
Pediatric Dose<18 years: Not recommended
>18 years: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsAntacids, iron salts, and zinc salts may reduce serum levels; administer antacids 2-4 h before or after taking fluoroquinolones; cimetidine may interfere with metabolism of fluoroquinolones; ciprofloxacin reduces therapeutic effects of phenytoin; probenecid may increase ciprofloxacin serum concentrations; may increase toxicity of theophylline, caffeine, cyclosporine, and digoxin (monitor digoxin levels); may increase effects of anticoagulants (monitor PT)
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsIn prolonged therapy, perform periodic evaluations of organ system functions (eg, renal, hepatic, hematopoietic); adjust dose in patients with renal function impairment; superinfections may occur with prolonged or repeated antibiotic therapy; rarely causes crystalluria (avoid alkalinization; patients should be well hydrated); may cause adverse CNS effects (eg, anxiety, insomnia, nervousness, agitation, nightmares, paranoia); may cause sunburnlike photosensitivity (avoid excessive sunlight)

Drug NameAzithromycin (Zithromax)
DescriptionTreats mild-to-moderate microbial infections.
Adult DoseTyphoid fever: 1000 mg PO qd for 5 d or
1000 mg PO on d 1 followed by 500 mg PO qd for 6 d
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; hepatic impairment; do not administer with pimozide
InteractionsMay increase toxicity of theophylline, warfarin, and digoxin; effects are reduced with coadministration of aluminum and/or magnesium antacids; nephrotoxicity and neurotoxicity may occur when coadministered with cyclosporine
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsSite reactions can occur with IV route; bacterial or fungal overgrowth may result with prolonged antibiotic use; may increase hepatic enzymes and cholestatic jaundice; caution in patients with impaired hepatic function, prolonged QT intervals, or pneumonia; caution in patients who are hospitalized, older, or debilitated

Drug NameCeftriaxone (Rocephin)
DescriptionThird-generation cephalosporin with broad-spectrum gram-negative activity; lower efficacy against gram-positive organisms; higher efficacy against resistant organisms. Arrests bacterial growth by binding to one or more penicillin-binding proteins.
Adult DoseTyphoid fever: 2-3 g IV qd for 7-14 d
Pediatric Dose50-75 mg/kg IV q12h
ContraindicationsDocumented hypersensitivity
InteractionsProbenecid may increase ceftriaxone levels; coadministration with ethacrynic acid, furosemide, and aminoglycosides may increase nephrotoxicity
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsCaution in women who are breastfeeding; caution in individuals with a history of gastrointestinal disease; not to be administered to preterm or neonates; may cause pseudobiliary lithiasis

Drug NameTrimethoprim and sulfamethoxazole (Bactrim DS, Septra)
DescriptionInhibits bacterial growth by inhibiting synthesis of dihydrofolic acid. Antibacterial activity of TMP-SMZ includes common urinary tract pathogens, except P aeruginosa.
Adult DoseGastroenteritis: 160 mg TMP/800 mg SMZ PO bid for 3-5 d
Pediatric Dose<2 months: Do not administer
>2 months: 8 mg/kg/d TMP and 40mg/kg/d SMZ PO bid
ContraindicationsDocumented hypersensitivity; megaloblastic anemia due to folate deficiency
InteractionsMay increase PT when used with warfarin (perform coagulation tests and adjust dose accordingly); coadministration with dapsone may increase blood levels of both drugs; coadministration of diuretics increases incidence of thrombocytopenia purpura in elderly; phenytoin levels may increase with coadministration; may potentiate effects of methotrexate in bone marrow depression; hypoglycemic response to sulfonylureas may increase with coadministration; may increase levels of zidovudine; may cause nephrotoxicity when coadministered with cyclosporine; indomethacin may increase serum sulfamethoxazole levels; may cause megaloblastic anemia in patients concurrently receiving pyrimethamine; may decrease efficacy of TCAs
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsDiscontinue at first appearance of skin rash or sign of adverse reaction; obtain CBCs frequently; discontinue therapy if significant hematologic changes occur; goiter, diuresis, and hypoglycemia may occur with sulfonamides; prolonged IV infusions or high doses may cause bone marrow depression (if signs occur, administer 5-15 mg/d leucovorin); caution in patients with folate deficiency (eg, chronic alcoholism, advanced age, anticonvulsant therapy, malabsorption syndrome); hemolysis may occur in individuals with G-6-PD deficiency; patients with AIDS may not tolerate or respond to TMP-SMX; caution in patients with renal or hepatic impairment (perform urinalyses and renal function tests during therapy); administer fluids to prevent crystalluria and stone formation

Drug NameChloramphenicol (Chloromycetin)
DescriptionBinds to 50S bacterial-ribosomal subunits and inhibits bacterial growth by inhibiting protein synthesis. Effective against gram-negative and gram-positive bacteria. PO formulation unavailable in the United States.
Adult DoseTyphoid fever: 500 mg PO/IV qid for 14 d
Pediatric Dose75-100 mg/kg/d
ContraindicationsDocumented hypersensitivity; bone marrow depression; impaired hepatic function
InteractionsConcurrently with barbiturates, chloramphenicol serum levels may decrease while barbiturate levels may increase causing toxicity; manifestations of hypoglycemia may occur with sulfonylureas; rifampin may reduce serum chloramphenicol levels, presumably through hepatic enzyme induction; may increase effects of anticoagulants; may increase serum hydantoin levels, possibly resulting in toxicity
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsUse only for indicated infections or as prophylaxis for bacterial infections; serious and fatal blood dyscrasias (eg, aplastic anemia, hypoplastic anemia, thrombocytopenia, granulocytopenia) can occur; evaluate baseline, and perform periodic blood studies approximately every 3 d while in therapy; discontinue upon appearance of reticulocytopenia, leukopenia, thrombocytopenia, anemia, dose-related adverse effects; caution in pregnancy at term or during labor because of potential toxic effects on fetus (gray syndrome); not recommended in women who are breastfeeding; serum concentrations must be performed in pediatric patients with impaired or immature metabolic functions or in patients who are receiving medications also metabolized by the liver



Deterrence/Prevention

  • The mode of Salmonella transmission is primarily oral. Disease prevention consequently includes proper sanitation and hygiene as well as the avoidance of insufficiently cooked or mishandled food.

Complications

  • Cardiovascular - Endocarditis, pericarditis, valve perforation, and arteritis
  • CNS - Meningitis, ventriculitis, and abscess
  • Pulmonary - Pneumonia, abscess, empyema, and bronchopleural fistula
  • Bone/joints - Osteomyelitis and septic arthritis
  • Hepatobiliary - Hepatic abscess, cholecystitis, and peritonitis
  • Splenic - Abscess
  • Urinary - Cystitis, pyelonephritis, and renal abscess
  • Genital - Ovarian abscess, testicular abscess, prostatitis, and epididymitis
  • Soft tissue - Abscess

Prognosis

  • Nontyphoidal salmonellosis is generally self-limiting, with symptoms typically lasting no longer than 3-7 days.
  • Patients occasionally require hospitalization, but death is rare ( <1%).
  • After resolution of symptoms, the mean duration of fecal shedding of Salmonella is 4-5 weeks, depending on the strain.
  • In the absence of risk factors for severe disease, limit treatment to symptomatic care and fluid and electrolyte repletion. Indeed, some studies suggest that antibiotics actually prolong the carrier state.
  • In the preantibiotic era, approximately 15% of patients with typhoid fever died. More recently, mortality rates as high as 30% have been reported in certain developing countries. The mortality rate for patients with typhoid fever who are appropriately treated is less than 1%.

Patient Education

  • Because salmonellae are ubiquitous, their eradication is unlikely. Consequently, a mainstay of disease prevention and control is public education.
  • Because transmission primarily occurs through ingestion of contaminated foods, inform people about the importance of sanitary food handling, proper food preparation, and personal hygiene.
  • Notably, the emergence of drug-resistant salmonellae illustrates the importance of responsible antibiotic use in medicine and animal husbandry.



Medical/Legal Pitfalls

  • Although generally self-limiting, salmonellosis may be severe in patients who are debilitated, immunocompromised, or at the extremes of age. Failure to correctly diagnose and treat these individuals could result in adverse outcomes.



  • Aserkoff B, Bennett JV. Effect of antibiotic therapy in acute salmonellosis on the fecal excretion of salmonellae. N Engl J Med. Sep 18 1969;281(12):636-40. [Medline].
  • Buchwald DS, Blaser MJ. A review of human salmonellosis: II. Duration of excretion following infection with nontyphi Salmonella. Rev Infect Dis. May-Jun 1984;6(3):345-56. [Medline].
  • Cunha BA. Antibiotic Essentials. Royal Oak, Mich:. Physicians Press;2005.
  • Darwin KH, Miller VL. Molecular basis of the interaction of Salmonella with the intestinal mucosa. Clin Microbiol Rev. Jul 1999;12(3):405-28. [Medline].
  • Edwards BH. Salmonella and Shigella species. Clin Lab Med. Sep 1999;19(3):469-87, v. [Medline].
  • Finlay BB. Molecular and cellular mechanisms of Salmonella pathogenesis. Curr Top Microbiol Immunol. 1994;192:163-85. [Medline].
  • Helms M, Simonsen J, Molbak K. Quinolone resistance is associated with increased risk of invasive illness or death during infection with Salmonella serotype Typhimurium. J Infect Dis. Nov 1 2004;190(9):1652-4. [Medline].
  • Hsu RB, Chen RJ, Chu SH. Risk factors for recurrent bacteremia in adult patients with nontyphoid salmonellosis. Am J Med Sci. Dec 2004;328(6):315-8. [Medline].
  • Kennedy M, Villar R, Vugia DJ, et al. Hospitalizations and deaths due to Salmonella infections, FoodNet, 1996-1999. Clin Infect Dis. Apr 15 2004;38 Suppl 3:S142-8. [Medline].
  • Kotloff KL. Bacterial diarrheal pathogens. Adv Pediatr Infect Dis. 1999;14:219-67. [Medline].
  • Lax AJ, Barrow PA, Jones PW, Wallis TS. Current perspectives in salmonellosis. Br Vet J. Jul-Aug 1995;151(4):351-77. [Medline].
  • Marimon JM, Gomariz M, Zigorraga C, et al. Increasing prevalence of quinolone resistance in human nontyphoid Salmonella enterica isolates obtained in Spain from 1981 to 2003. Antimicrob Agents Chemother. Oct 2004;48(10):3789-93. [Medline].
  • Mead PS, Slutsker L, Dietz V, et al. Food-related illness and death in the United States. Emerg Infect Dis. Sep-Oct 1999;5(5):607-25. [Medline].
  • Mermin J, Hutwagner L, Vugia D, et al. Reptiles, amphibians, and human Salmonella infection: a population-based, case-control study. Clin Infect Dis. Apr 15 2004;38 Suppl 3:S253-61. [Medline].
  • Mermin JH, Townes JM, Gerber M, et al. Typhoid fever in the United States, 1985-1994: changing risks of international travel and increasing antimicrobial resistance. Arch Intern Med. Mar 23 1998;158(6):633-8. [Medline].
  • Miller SI, Pegues DA. Salmonella species, including Salmonella typhi. In: Mandell, et al, ed. Principles and Practices of Infectious Diseases. 5th ed. 2000;2:2344-62.
  • Nelson JD, Kusmiesz H, Jackson LH, Woodman E. Treatment of Salmonella gastroenteritis with ampicillin, amoxicillin, or placebo. Pediatrics. Jun 1980;65(6):1125-30. [Medline].
  • Rabatsky-Ehr T, Whichard J, Rossiter S, et al. Multidrug-resistant strains of Salmonella enterica Typhimurium, United States, 1997-1998. Emerg Infect Dis. May 2004;10(5):795-801. [Medline].
  • Schroeder CM, Naugle AL, Schlosser WD, et al. Estimate of illnesses from Salmonella enteritidis in eggs, United States, 2000. Emerg Infect Dis. Jan 2005;11(1):113-5. [Medline].
  • Van Immerseel F, Pasmans F, De Buck J, et al. Cats as a risk for transmission of antimicrobial drug-resistant Salmonella. Emerg Infect Dis. Dec 2004;10(12):2169-74. [Medline].
  • Voetsch AC, Van Gilder TJ, Angulo FJ, et al. FoodNet estimate of the burden of illness caused by nontyphoidal Salmonella infections in the United States. Clin Infect Dis. Apr 15 2004;38 Suppl 3:S127-34. [Medline].
  • Weinberger M, Andorn N, Agmon V, et al. Blood invasiveness of Salmonella enterica as a function of age and serotype. Epidemiol Infect. Dec 2004;132(6):1023-8. [Medline].

Salmonellosis excerpt

Article Last Updated: Aug 1, 2005